Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Abstract Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase inhibitor,...